Prelabeling of chimeric monoclonal antibody L6 with 90yttrium- and 111indium-1,4,7,10-tetraazacyclododecane-N,N',N",N"'-tetraacetic acid (DOTA) chelates for radioimmunodiagnosis and therapy

Cancer Res. 1995 Dec 1;55(23 Suppl):5726s-5728s.

Abstract

90Y and 111In have been attached to chimeric monoclonal antibody L6 with a bifunctional chelating agent (DOTA-peptide isothiocyanate). The bifunctional chelating agent was prelabeled with either radiometal and then conjugated to the antibody. Studies in human patients showed excellent 111In single-photon emission computed tomography images of breast cancer lesions 24 h after injection.

Publication types

  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Animals
  • Antibodies, Bispecific / chemistry
  • Antibodies, Bispecific / immunology
  • Antibodies, Bispecific / therapeutic use
  • Antibodies, Monoclonal / chemistry*
  • Antibodies, Monoclonal / immunology
  • Antibodies, Monoclonal / therapeutic use
  • Antibodies, Neoplasm / chemistry*
  • Antibodies, Neoplasm / immunology
  • Antibodies, Neoplasm / therapeutic use
  • Breast Neoplasms / immunology
  • Breast Neoplasms / radiotherapy*
  • Drug Delivery Systems
  • Female
  • Heterocyclic Compounds
  • Heterocyclic Compounds, 1-Ring*
  • Humans
  • Indium Radioisotopes*
  • Isotope Labeling*
  • Mice
  • Mice, Nude
  • Radioimmunotherapy*
  • Tomography, Emission-Computed, Single-Photon
  • Yttrium Radioisotopes*

Substances

  • Antibodies, Bispecific
  • Antibodies, Monoclonal
  • Antibodies, Neoplasm
  • Heterocyclic Compounds
  • Heterocyclic Compounds, 1-Ring
  • Indium Radioisotopes
  • Yttrium Radioisotopes
  • 1,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acid